By Paul Armentano, NORML Deputy Director
Israeli investigators intend to evaluate the potential anti-tumoral effects of the canabinoid cannabidiol (CBD) in select cancer patients.
In August, pharmaceutical provider Insys Therapeutics announced that it had received orphan drug status for its proprietary formulation of CBD for the treatment of glioblastoma, a hard-to-treat, aggressive form of brain cancer.
Further details of the forthcoming Israeli trial are available online from the clinicaltrials.gov website here. Patient recruitment has yet to begin for this study.